|
1
|
Surveillance epidemiology and end results
SEER stat fact sheets: Lung and bronchus cancer. 2016.http://seer.cancer.gov/statfacts/html/lungb.htmlNovember
17–2016
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zago G, Muller M, van den Heuvel M and
Baas P: New targeted treatments for non-small-cell lung cancer-role
of nivolumab. Biologics. 10:103–117. 2016.PubMed/NCBI
|
|
5
|
Non-small cell lung cancer treatment
(PDQ®)-patient version. 2016, https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdqNovember
17–2016
|
|
6
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E,
Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, et al:
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J
Med. 370:1189–1197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meroni G and Diez-Roux G: TRIM/RBCC, a
novel class of ‘single protein RING finger’ E3 ubiquitin ligases.
Bioessays. 27:1147–1157. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ikeda K and Inoue S: TRIM proteins as RING
finger E3 ubiquitin ligases. Adv Exp Med Biol. 770:27–37. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamada Y, Takayama KI, Fujimura T,
Ashikari D, Obinata D, Takahashi S, Ikeda K, Kakutani S, Urano T,
Fukuhara H, Homma Y, et al: A novel prognostic factor TRIM44
promotes cell proliferation and migration, and inhibits apoptosis
in testicular germ cell tumor. Cancer Sci. 180:32–41. 2017.
View Article : Google Scholar
|
|
16
|
Wang J, Zhu J, Dong M, Yu H, Dai X and Li
K: Knockdown of tripartite motif containing 24 by lentivirus
suppresses cell growth and induces apoptosis in human colorectal
cancer cells. Oncol Res. 22:39–45. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhan W, Han T, Zhang C, Xie C, Gan M, Deng
K, Fu M and Wang JB: TRIM59 promotes the proliferation and
migration of non-small cell lung cancer cells by upregulating cell
cycle related proteins. PLoS One. 10:e01425962015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bell JL, Malyukova A, Kavallaris M,
Marshall GM and Cheung BB: TRIM16 inhibits neuroblastoma cell
proliferation through cell cycle regulation and dynamic nuclear
localization. Cell Cycle. 12:889–898. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Shi W, Shi H, Lu S, Wang K, Sun C,
He J, Jin W, Lv X, Zou H and Shu Y: TRIM11 overexpression promotes
proliferation, migration and invasion of lung cancer cells. J Exp
Clin Cancer Res. 35:1002016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen L, Muñoz-Antonia T and Cress WD:
Trim28 contributes to EMT via regulation of E-cadherin and
N-cadherin in lung cancer cell lines. PLoS One. 9:e1010402014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song X, Fu C, Yang X, Sun D, Zhang X and
Zhang J: Tripartite motif-containing 29 as a novel biomarker in
non-small cell lung cancer. Oncol Lett. 10:2283–2288.
2015.PubMed/NCBI
|
|
22
|
Luo Q, Lin H, Ye X, Huang J, Lu S and Xu
L: Trim44 facilitates the migration and invasion of human lung
cancer cells via the NF-κB signaling pathway. Int J Clin Oncol.
20:508–517. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Khatamianfar V, Valiyeva F, Rennie PS, Lu
WY, Yang BB, Bauman GS, Moussa M and Xuan JW: TRIM59, a novel
multiple cancer biomarker for immunohistochemical detection of
tumorigenesis. BMJ Open. 2:pii:e0014102012. View Article : Google Scholar
|
|
24
|
Zhou Z, Ji Z, Wang Y, Li J, Cao H, Zhu HH
and Gao WQ: TRIM59 is up-regulated in gastric tumors, promoting
ubiquitination and degradation of p53. Gastroenterology.
147:1043–1054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang J, Xing D, Li Z, Shen J, Zhao H and
Li S: TRIM59 is upregulated and promotes cell proliferation and
migration in human osteosarcoma. Mol Med Rep. 13:5200–5206.
2016.PubMed/NCBI
|
|
26
|
Aierken G, Seyiti A, Alifu M and Kuerban
G: Knockdown of tripartrtite-59 (TRIM59) inhibits cellular
proliferation and migration in human cervical cancer cells. Oncol
Res. 25:381–388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Valiyeva F, Jiang F, Elmaadawi A, Moussa
M, Yee SP, Raptis L, Izawa JI, Yang BB, Greenberg NM, Wang F and
Xuan JW: Characterization of the oncogenic activity of the novel
TRIM59 gene in mouse cancer models. Mol Cancer Ther. 10:1229–1240.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC,
Lin CW, Shih JY, Yang PC, Hsiao CK, Lai LC and Chuang EY:
Identification of a novel biomarker, SEMA5A, for non-small cell
lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers
Prev. 19:2590–2597. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rousseaux S, Debernardi A, Jacquiau B,
Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY,
Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and
placental genes identifies aggressive metastasis-prone lung
cancers. Sci Transl Med. 5:186ra662013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Okayama H, Kohno T, Ishii Y, Shimada Y,
Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S,
et al: Identification of genes upregulated in ALK-positive and
EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res.
72:100–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yamauchi M, Yamaguchi R, Nakata A, Kohno
T, Nagasaki M, Shimamura T, Imoto S, Saito A, Ueno K, Hatanaka Y,
et al: Epidermal growth factor receptor tyrosine kinase defines
critical prognostic genes of stage I lung adenocarcinoma. PLoS One.
7:e439232012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Selamat SA, Chung BS, Girard L, Zhang W,
Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, et al:
Genome-scale analysis of DNA methylation in lung adenocarcinoma and
integration with mRNA expression. Genome Res. 22:1197–1211. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Botling J, Edlund K, Lohr M, Hellwig B,
Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, et
al: Biomarker discovery in non-small cell lung cancer: Integrating
gene expression profiling, meta-analysis, and tissue microarray
validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tarca AL, Lauria M, Unger M, Bilal E, Boue
S, Dey K Kumar, Hoeng J, Koeppl H, Martin F, Meyer P, et al:
Strengths and limitations of microarray-based phenotype prediction:
Lessons learned from the IMPROVER diagnostic signature challenge.
Bioinformatics. 29:2892–2899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:pp. 15545–15550. 2005;
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Szklarczyk D, Franceschini A, Kuhn M,
Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork
P, et al: The STRING database in 2011: Functional interaction
networks of proteins, globally integrated and scored. Nucleic Acids
Res. 39:D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Y, Wang DC, Shi L, Zhu B, Min Z and
Jin J: Genome analyses identify the genetic modification of lung
cancer subtypes. Semin Cancer Biol. 42:20–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ozato K, Shin DM, Chang TH and Morse HC
III: TRIM family proteins and their emerging roles in innate
immunity. Nat Rev Immunol. 8:849–860. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McNab FW, Rajsbaum R, Stoye JP and O'Garra
A: Tripartite-motif proteins and innate immune regulation. Curr
Opin Immunol. 23:46–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chan E, Towers GJ and Qasim W: Gene
therapy strategies to exploit TRIM derived restriction factors
against HIV-1. Viruses. 6:243–263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Reck M, Popat S, Reinmuth N, De Ruysscher
D, Kerr KM and Peters S; ESMO Guidelines Working Group, :
Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 25 Suppl 3:iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zaytseva YY, Valentino JD, Gulhati P and
Evers BM: mTOR inhibitors in cancer therapy. Cancer Lett. 319:1–7.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cheng H, Walls M, Baxi SM and Yin MJ:
Targeting the mTOR pathway in tumor malignancy. Curr Cancer Drug
Targets. 13:267–277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Moschetta M, Reale A, Marasco C, Vacca A
and Carratù MR: Therapeutic targeting of the mTOR-signalling
pathway in cancer: Benefits and limitations. Br J Pharmacol.
171:3801–3813. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen R, Duan J, Li L, Ma Q, Sun Q, Ma J,
Li C, Zhou X, Chen H, Jing Y, et al: mTOR promotes pituitary tumor
development through activation of PTTG1. Oncogene. 36:979–988.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mai H, Xu X, Mei G, Hong T, Huang J, Wang
T, Yan Z, Li Y, Liang Y, Li L, et al: The interplay between HPIP
and casein kinase 1α promotes renal cell carcinoma growth and
metastasis via activation of mTOR pathway. Oncogenesis. 5:e2602016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhuang H, Bai J, Chang JY, Yuan Z and Wang
P: MTOR inhibition reversed drug resistance after combination
radiation with erlotinib in lung adenocarcinoma. Oncotarget.
7:84688–84694. 2016.PubMed/NCBI
|
|
49
|
Eltschinger S and Loewith R: TOR complexes
and the maintenance of cellular homeostasis. Trends Cell Biol.
26:148–159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Willems L, Tamburini J, Chapuis N, Lacombe
C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in
cancer: New data on targeted therapies. Curr Oncol Rep. 14:129–138.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tsujita Y, Mitsui-Sekinaka K, Imai K, Yeh
TW, Mitsuiki N, Asano T, Ohnishi H, Kato Z, Sekinaka Y, Zaha K, et
al: Phosphatase and tensin homolog (PTEN) mutation can cause
activated phosphatidylinositol 3-kinase δ syndrome-like
immunodeficiency. J Allergy Clin Immunol. 138:1672–1680.e10. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Habib SL, Al-Obaidi NY, Nowacki M, Pietkun
K, Zegarska B, Kloskowski T, Zegarski W, Drewa T, Medina EA, Zhao Z
and Liang S: Is mTOR inhibitor good enough for treatment all tumors
in TSC patients? J Cancer. 7:1621–1631. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Müller E, Bauer S, Stühmer T, Mottok A,
Scholz CJ, Steinbrunn T, Brünnert D, Brandl A, Schraud H, Kreßmann
S, et al: Pan-Raf co-operates with PI3K-dependent signalling and
critically contributes to myeloma cell survival independently of
mutated RAS. Leukemia. 31:922–933. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li L, Liu D, Qiu ZX, Zhao S, Zhang L and
Li WM: The prognostic role of mTOR and p-mTOR for survival in
non-small cell lung cancer: A systematic review and meta-analysis.
PLoS One. 10:e01167712015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Azim HA, Kassem L, Treilleux I, Wang Q, El
Enein MA, Anis SE and Bachelot T: Analysis of PI3K/mTOR pathway
biomarkers and their prognostic value in women with hormone
Receptor-Positive, HER2-Negative early breast cancer. Transl Oncol.
9:114–123. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xiao L, Wang YC, Li WS and Du Y: The role
of mTOR and phospho-p70S6K in pathogenesis and progression of
gastric carcinomas: An immunohistochemical study on tissue
microarray. J Exp Clin Cancer Res. 28:1522009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li S, Wang Z, Huang J, Cheng S, Du H, Che
G and Peng Y: Clinicopathological and prognostic significance of
mTOR and phosphorylated mTOR expression in patients with esophageal
squamous cell carcinoma: A systematic review and meta-analysis. BMC
Cancer. 16:8772016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wendel HG, Silva RL, Malina A, Mills JR,
Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J,
Pelletier J and Lowe SW: Dissecting eIF4E action in tumorigenesis.
Genes Dev. 21:3232–3237. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Li Y, Fan S, Koo J, Yue P, Chen ZG,
Owonikoko TK, Ramalingam SS, Khuri FR and Sun SY: Elevated
expression of eukaryotic translation initiation factor 4E is
associated with proliferation, invasion and acquired resistance to
erlotinib in lung cancer. Cancer Biol Ther. 13:272–280. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Thumma SC, Jacobson BA, Patel MR, Konicek
BW, Franklin MJ, Jay-Dixon J, Sadiq A, De A, Graff JR and Kratzke
RA: Antisense oligonucleotide targeting eukaryotic translation
initiation factor 4E reduces growth and enhances chemosensitivity
of non-small-cell lung cancer cells. Cancer Gene Ther. 22:396–401.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Khoury T, Alrawi S, Ramnath N, Li Q, Grimm
M, Black J and Tan D: Eukaryotic initiation factor-4E and cyclin D1
expression associated with patient survival in lung cancer. Clin
Lung Cancer. 10:58–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Li Y, Wu H, Wu W, Zhuo W, Liu W, Zhang Y,
Cheng M, Chen YG, Gao N, Yu H, et al: Structural insights into the
TRIM family of ubiquitin E3 ligases. Cell Res. 24:762–765. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tomar D, Prajapati P, Lavie J, Singh K,
Lakshmi S, Bhatelia K, Roy M and Singh R, Bénard G and Singh R:
TRIM4; a novel mitochondrial interacting RING E3 ligase, sensitizes
the cells to hydrogen peroxide (H2O2) induced cell death. Free
Radic Biol Med. 89:1036–1048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu J, Zhang C, Wang XL, Ly P, Belyi V,
Xu-Monette ZY, Young KH, Hu W and Feng Z: E3 ubiquitin ligase
TRIM32 negatively regulates tumor suppressor p53 to promote
tumorigenesis. Cell Death Differ. 21:1792–1804. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhu Z, Wang Y, Zhang C, Yu S, Zhu Q, Hou K
and Yan B: TRIM25 blockade by RNA interference inhibited migration
and invasion of gastric cancer cells through TGF-β signaling. Sci
Rep. 6:190702016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Koseoglu S, Lu Z, Kumar C, Kirschmeier P
and Zou J: AKT1, AKT2 and AKT3-dependent cell survival is cell
line-specific and knockdown of all three isoforms selectively
induces apoptosis in 20 human tumor cell lines. Cancer Biol Ther.
6:755–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Liu Y, Gao X, Deeb D, Zhang Y, Shaw J,
Valeriote FA and Gautam SC: Mycotoxin verrucarin A inhibits
proliferation and induces apoptosis in prostate cancer cells by
inhibiting prosurvival Akt/NF-κB/mTOR signaling. J Exp Ther Oncol.
11:251–260. 2016.PubMed/NCBI
|
|
69
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hsieh AC, Nguyen HG, Wen L, Edlind MP,
Carroll PR, Kim W and Ruggero D: Cell type-specific abundance of
4EBP1 primes prostate cancer sensitivity or resistance to PI3K
pathway inhibitors. Sci Signal. 8:ra1162015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lee HW, Lee EH, Lee JH, Kim JE, Kim SH,
Kim TG, Hwang SW and Kang KW: Prognostic significance of
phosphorylated 4E-binding protein 1 in non-small cell lung cancer.
Int J Clin Exp Pathol. 8:3955–3962. 2015.PubMed/NCBI
|
|
72
|
Roh MS, Lee JH, Kang KW, Nam HY, Jung SB,
Kim K, Lee EH, Park MI, Kim MS and Lee HW: Phosphorylated
4E-binding protein 1 expression is associated with poor prognosis
in small-cell lung cancer. Virchows Arch. 467:667–673. 2015.
View Article : Google Scholar : PubMed/NCBI
|
